Trelegy Ellipta (Fluticasone furoate/Umeclidinium Bromide/Vilanterol Trifenatate)

Trelegy Ellipta

(Brand Option)

Prescription RequiredPrescription Required
FormulationFormulation: Inhalation Powder
Select Dosage

Select Quantity







Fluticasone furoate/Umeclidinium Bromide/Vilanterol Trifenatate

(Generic Alternative)

Prescription RequiredPrescription Required

This generic medication is not available at the moment.

Norton Shopping Guarantee

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting 2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting 2-agonist (LABA).

It is also indicated for the maintenance treatment of asthma in patients aged 18 years and older. 

Trelegy Ellipta contains three active substances; an inhaled corticosteroid (fluticasone furoate) and two bronchodilators (umeclidinium and vilanterol).


  • Before starting to use Trelegy Ellipta and each time you get a refill, read the Patient Information Leaflet and Instructions for Use provided by your pharmacist. Follow the illustrated directions for the proper use of this medication. If there are any questions, ask your healthcare provider.
  • Trelegy Ellipta is typically inhaled by mouth as directed by a healthcare provider, usually once daily.
  • This medication must be used regularly at the same time every day to be effective and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, a quick-relief inhaler should be used as prescribed. 
  • To prevent dry mouth, hoarseness, and oral yeast infections, gargle, rinse the mouth with water, and spit out after each use. 
  • The mouthpiece of the inhaler may be cleaned using a dry tissue before closing the cover.
  • If using other inhalers at the same time, wait at least 1 minute between the use of each medication.
  • If using a quick-relief inhaler on a regular daily schedule, consult a healthcare provider for details on how to adjust the use of the quick-relief inhaler.
  • Continue using any other prescribed medications, such as corticosteroids, as directed by the healthcare provider. 
  • Inform your healthcare provider if your condition does not improve or if it gets worse. 


  • Do not open the cover of the inhaler until ready to use it. Each time the cover is opened, a dose of the medication is prepared.  Do not open and close the cover without inhaling the medication to avoid losing the dose.
  • After inhaling the medication, avoid exhaling into the device. 
  • Do not use this medication more than once each day. 
  • Do not increase the dose, use the medication more often, or stop using it without consulting a healthcare provider
  • Do not swallow the rinse water after washing your mouth.

Common Side Effects:

  • Sore throat
  • Cough

Less Common, but more Serious Side Effects:

  • Glaucoma 
  • Cataracts.

Serious Side Effects:

  • Bladder pain
  • Bloody or cloudy urine
  • Chest pain or tightness
  • Chills
  • Cough
  • Diarrhea
  • Difficult, burning, or painful urination
  • Fever
  • Frequent urge to urinate
  • Headache
  • Loss of appetite
  • Lower back or side pain
  • Nausea
  • Pain in the nose and mouth

If you experience any of these side effects, seek medical attention.

Consult your healthcare provider for more information about the side effects of Trelegy Ellipta and discuss any concerns you may have.

Trelegy Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. It has not been studied in subjects with acutely deteriorating COPD and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.

Trelegy Ellipta can cause paradoxical bronchospasm. If this occurs, patients should discontinue Trelegy Ellipta and contact their healthcare provider right away.

Hypersensitivity reactions, including anaphylaxis, may occur after the administration of Trelegy Ellipta. Patients should discontinue Trelegy Ellipta if such reactions occur.

Long-term use of Trelegy Ellipta may lead to a reduction in bone mineral density. Patients should be monitored for this potential effect.

Patients with current viral, bacterial, parasitic, or fungal infections should inform their healthcare provider before using Trelegy Ellipta, as this medication can decrease the immune system's ability to fight an infection.

It's not known whether Trelegy Ellipta is safe to use during pregnancy or while breastfeeding. Patients should seek medical advice in these situations.

Generic name:

Fluticasone furoate/Umeclidinium Bromide/Vilanterol Trifenatate, Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate


Inhalation Powder

Strength(s): 100/62.5/25mcg, 200/62.5/25mcg
Quantities Available: 30, 30, 60, 90
Important Information
The information above for Trelegy Ellipta (Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate) was provided to by third parties. In no way should this information substitute for the advice of a physician. Consult a doctor or qualified health care professional if you have any medical concerns. widget logo
Customer Care Customer Care

Excellent Customer Care We Are Here for You

Guiding you every step of the way, ensuring access to affordable medicines. Our customer service team is available seven days a week to answer any questions or to address any concerns you may have. Please give us a call at Doctor Solve on Monday to Friday from 6am-8pm PST, or Saturdays and Sundays from 7am-5pm PST.